Skip to content Skip to footer
Subscribe Now
PharmaShots Interview Fountain Therapeutics’ William Greene Shares Insights on the $15M Series A-2 Financing
VIEWPOINTS
PharmaShots Interview: Fountain Therapeutics’ William Greene Shares Insights on the $15M Series A-2 Financing
In an interview with PharmaShots, William Greene, CEO at Fountain Therapeutics shares his views on the closing of $15M Series A-2 financing & how it supports the drug discovery platform and pipelineShots:The company closes $15M series A-2 financing bringing its total Series A funding to $26M which was led by Eli Lilly, Alexandria Venture Investments, and R42 Group as new…
April 13, 20220Comments
PharmaShots Interview Medidata’s Kelly McKee Shares Insight on Decentralized Clinical Trial
VIEWPOINTS
PharmaShots Interview: Medidata’s Kelly McKee Shares Insight on Decentralized Clinical Trial
In an interview with PharmaShots, Kelly McKee, Vice President, Patient Registries & Recruitment at Medidata shared her views on the decentralized clinical trial networks through the collaboration with Circuit ClinicalShots:Medidata is investing $27M in Circuit Clinical’s series C funding. Circuit Clinical will expand its DCT network to 500 physicians & 15M patients & bring clinical research as…
April 12, 20220Comments
PharmaShots Interview Abbott’s Allen Burton Shares Insight on Proclaim XR Spinal Cord Stimulation System for the Treatment of Chronic Intractable Pain of Trunk and Limbs
VIEWPOINTS
PharmaShots Interview: Abbott’s Allen Burton Shares Insight on Proclaim XR Spinal Cord Stimulation System for the Treatment of Chronic Intractable Pain of Trunk and Limbs
In an interview with PharmaShots, Dr. Allen Burton, Medical Director of Abbott’s Neuromodulation Business shared his views on the US FDA approval for expanded MRI compatibility of Its Proclaim XR SCS DeviceShots:The US FDA has approved new expanded MRI compatibility for its Proclaim XR Spinal Cord Stimulation (SCS) System with Octrode leads. The Proclaim XR SCS System is an…
April 11, 20220Comments
Insights+ Key Biosimilars Events of March 2022
INSIGHTS+
Insights+ Key Biosimilars Events of March 2022
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patientsDuring the month of March, Junshi & Mabwell Bioscience’s Junmaikang (biosimilar, adalimumab)…
April 7, 20220Comments
PharmaShots Interview SOTIO Richard Sachse Shares Insight on SOT101 for the Treatment of Advanced Metastatic Solid Tumors
VIEWPOINTS
PharmaShots Interview: SOTIO’ Richard Sachse Shares Insight on SOT101 for the Treatment of Advanced/Metastatic Solid Tumors
In an interview with PharmaShots, Richard Sachse, Chief Medical Officer & Managing Director at SOTIO shared his views on the data of SOT101 in the P-I/Ib (AURELIO-03) study for the treatment of advanced/metastatic solid tumorsShots:The P-I/Ib (AURELIO-03) study evaluates SOT101 as monothx. & in combination with pembrolizumab in patients with advanced/metastatic solid tumorsThe results showed that 13 patients…
April 6, 20220Comments
PharmaShots Interview Ikena Oncology’ Mark Manfredi Shares Insight on IK-930 for the Treatment of Solid Tumors
VIEWPOINTS
PharmaShots Interview: Ikena Oncology’ Mark Manfredi Shares Insight on IK-930 for the Treatment of Solid Tumors
In an interview with PharmaShots, Mark Manfredi, President, and CEO at Ikena Oncology shared his views on the US FDA’s IND clearance of IK-930 for the treatment of solid tumors that harbors genetic alterations in the hippo pathwayShots:The US FDA has accepted its IND application to initiate the P-I study of IK-930 for solid tumors harboring genetic alterations in the…
April 5, 20220Comments
PharmaShots Interview Frank Leebeek & Greta Mulder of Erasmus MC, Lutz Bonacker of CSL Behring Share Insight on Etranacogene Dezaparvovec for the Treatment of Hemophilia B
VIEWPOINTS
PharmaShots Interview: Frank Leebeek & Greta Mulder of Erasmus MC, Lutz Bonacker of CSL Behring Share Insight on Etranacogene Dezaparvovec for the Treatment of Hemophilia B
In an interview with PharmaShots, Frank Leebeek, MD, Ph.D., Hematology Department Head & Greta Mulders, Nurse Practitioner, Study Coordinator at the Erasmus Medical Center in Rotterdam, Lutz Bonacker, Senior Vice President, General Manager, Commercial Operations Europe at CSL Behring shared their views on the data of Etranacogene Dezaparvovec in P-III (HOPE-B) trial for the treatment of Hemophilia B, presented at EAHAD 2022…
April 4, 20220Comments
PharmaShots' Key Highlights of First Quarter 2022
INSIGHTS+
PharmaShots’ Key Highlights of First Quarter 2022
The first quarter of 2022 highlights the approvals, clinical data & acquisitions. There are major alliances in this quarter which include Biocon acquired Viatris’ biosimilars assets for ~$3.335B, Stryker signed a definitive agreement to acquire Vocera Communications for ~$3.09B, Biohaven acquire Channel Biosciences for ~$3BThe first quarter of the year also showcases regulatory events…
March 31, 20220Comments
PharmaShots Interview Seattle Children’s Research Institute’ Fred David Mast Shares Insight on Nanobodies for the Prevention of COVID-19
VIEWPOINTS
PharmaShots Interview: Seattle Children’s Research Institute’ Fred David Mast Shares Insight on Nanobodies for the Prevention of COVID-19
In an interview with PharmaShots, Fred David Mast, Senior Research Scientist at Seattle Children’s Research Institute shared his views on the study demonstrating that Nanobodies could be an exceptional resource for superior COVID-19 protective and therapeutic interventions. The results of this study were published in E-lifeShots:Seattle Children’s Research Institute’s scientists collaborated with researchers from Rockefeller University to investigate the…
March 31, 20220Comments